Targeted, full-genomic next-generation sequencing for research use.
| Specimen | 2–4 mL of blood with anticoagulant EDTA |
|---|---|
| Lab method | Next generation sequencing. Our solution entails a targeted full-genomic sequencing approach that enables deep sequencing of a gene's complete genomic sequence, encompassing its enhancers, promoters, exons, shallow introns and, importantly, the deep introns. |
Autosomal recessive Stargardt disease is a juvenile-onset macular dystrophy associated with rapid central visual impairment, progressive bilateral atrophy of the foveal retinal pigment epithelium, and the frequent appearance of yellowish flecks around the macula and/or in the central and near-peripheral areas of the retina.
| Specimen | 2–4 mL of blood with anticoagulant EDTA |
|---|---|
| Lab method | Next generation sequencing. The UCD panel encompasses capture probes designed for eight genes, namely ARG1, ASL, ASS1, CPS1, NAGS, OTC, SLC25A13 and SLC25A15. Our solution entails a targeted full-genomic sequencing approach that enables deep sequencing of a gene's complete genomic sequence, encompassing its enhancers, promoters, exons, shallow introns and, importantly, the deep introns. |
| Gene | Condition |
|---|---|
| ARG1 | Argininemia |
| ASL | Argininosuccinic aciduria |
| ASS1 | Citrullinemia |
| CPS1 | Carbamoylphosphate synthetase I deficiency |
| NAGS | N-acetylglutamate synthase deficiency |
| OTC | Ornithine transcarbamylase deficiency |
| SLC25A13 | Citrullinemia, adult-onset type II; Citrullinemia, type II, neonatal-onset |
| SLC25A15 | Hyperornithinemia–hyperammonemia–homocitrullinemia syndrome |
Developed in collaboration with the A*STAR Institute of Molecular and Cell Biology (IMCB), this technology underpins Camtech's targeted full-genomic sequencing approach — enabling deep sequencing across a gene's complete genomic sequence, including its enhancers, promoters, exons and deep introns, to support diagnostics for genetic disorders such as ABCA4-retinopathy and urea cycle disorders.
Developing splice-switching oligonucleotides for urea cycle disorder using an integrated diagnostic and therapeutic platform
Ow JR, Imagawa E, Chen F, et al. J Hepatol. 2025 Aug;83(2):411–425. doi: 10.1016/j.jhep.2025.02.007
Read the publication →Get in touch to discuss specimen requirements, turnaround time and panel design for your research.